Chidamide

4 · 20 / page

Ask MedXY AI

Latest news

Tag

Hematology-OncologyAsparaginaseChidamide

Navigating Dual Resistance in Extranodal NK/T-Cell Lymphoma: Challenges and Emerging Insights

By MedXY|Jul 15, 2026

Dual resistance to asparaginase and PD-1 inhibitors in extranodal NK/T-cell lymphoma leads to poor prognosis; chidamide-containing regimens show promising survival benefits in this difficult-to-treat population.

Neoadjuvant Chidamide plus Anthracycline–Taxane Chemotherapy Yields a 35% RCB 0–I Rate in HR+/HER2– Breast Cancer: Early Phase 2 Results from MUKDEN 05

newsChidamideHDAC inhibitor

Chidamide

Latest news

Navigating Dual Resistance in Extranodal NK/T-Cell Lymphoma: Challenges and Emerging Insights

Neoadjuvant Chidamide plus Anthracycline–Taxane Chemotherapy Yields a 35% RCB 0–I Rate in HR+/HER2– Breast Cancer: Early Phase 2 Results from MUKDEN 05

Innovative All-Oral Therapy: Linperlisib Plus Chidamide Shows Promise in Relapsed or Refractory Cutaneous T-Cell Lymphoma

Linperlisib Plus Chidamide: A Promising Oral Therapy for Relapsed or Refractory Cutaneous T-Cell Lymphoma